Roubaix Capital LLC Invests $6.43 Million in Repligen Corporation $RGEN

Roubaix Capital LLC bought a new stake in Repligen Corporation (NASDAQ:RGEN) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 54,555 shares of the biotechnology company’s stock, valued at approximately $6,428,000. Repligen accounts for about 3.0% of Roubaix Capital LLC’s investment portfolio, making the stock its 9th largest holding.

A number of other large investors also recently made changes to their positions in the company. AQR Capital Management LLC purchased a new stake in Repligen in the 1st quarter valued at about $262,000. Jones Financial Companies Lllp grew its holdings in shares of Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after acquiring an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares during the period. Bank of Nova Scotia grew its position in Repligen by 88.0% during the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after buying an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in shares of Repligen by 29.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after purchasing an additional 7,148 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.60% of the stock is owned by company insiders.

Repligen Price Performance

RGEN stock opened at $147.25 on Friday. The firm has a 50 day moving average of $128.69 and a 200-day moving average of $133.52. The firm has a market capitalization of $8.31 billion, a P/E ratio of 163.61, a price-to-earnings-growth ratio of 2.84 and a beta of 1.06. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the prior year, the firm posted $0.39 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of several recent research reports. Roth Capital initiated coverage on Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective for the company. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday. Jefferies Financial Group restated a “hold” rating and set a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Evercore reaffirmed an “outperform” rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. Finally, HSBC reduced their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $165.00.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.